AR-targeted therapies sensitize prostate cancer to cuproptosis by transcriptionally activating FDX1
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
Proceedings of the National Academy of Sciences, Volume 123, Number 18, May 2026.
ImportanceResistance to androgen receptor (AR)-targeted therapies remains a major barrier to improving outcomes for patients with prostate cancer. This study reveals an unexpected molecular consequence of inhibition of the AR pathway by transcription…
